Diabetes & Cardiovascular Disease

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among patients with diabetes. Therefore, managing ASCVD risk is crucial in preventing the progression of atherosclerosis and reducing serious events like heart attacks and strokes in individuals with diabetes.

Medications for Type 2 Diabetes

It is important to note that the drug recommendations provided here are general and serve only as a guideline. The ultimate clinical decision should consider factors such as medication tolerability, cost, clinical context, glucose control, the patient’s weight loss goals, comorbidities, and patient preferences.

Clinical Trials on Diabetes Safety

In 2008, the Food and Drug Administration mandated the pharmaceutical industry to prove cardiovascular safety for all new anti-diabetes medications. As a consequence, we presently have critically useful safety data from clinical trials like LEADER, SUSTAIN, CANVAS, PIONEER 6, DECLARE-TIMI 58, and REWIND.

Key Revisions of 2020 ADA Guidelines

Here you can find the critical modifications in the 2020 ADA guidelines. Particular emphasis is placed on pharmacological therapy with GLP-1 agonists or SGLT-2 inhibitors for patients with established cardiovascular disease, heart failure, or chronic kidney disease. Guidelines are published yearly in January.

Testosterone for Women

Women accurately diagnosed with hypoactive sexual desire dysfunction (HSDD) and female sexual arousal disorder (FSAD) may benefit from testosterone supplementation. Testosterone therapy appears to be helpful and safe when the dose does not exceed premenopausal physiological levels.